사이나이 면역치료제(SCNI)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.24 (+1.04%), 시가총액 $0.00B, 52주 범위 $0.46 ~ $3.25.
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration pa
사이나이 면역치료제의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
사이나이 면역치료제의 현재 주가는 $0.24 (+1.04%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
사이나이 면역치료제의 시가총액은 약 $0.00B입니다.
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH